An estimated 2-5% of hospitalized patients are affected by AKI annually. Using a US population of 313 million people, 7% of which are hospitalized annually, and 2% of those affected, we get a market size of 457,000 people affected by AKI annually.
Studies have shown that those affected by AKI have a mean increase in cost of $15,900 usd.
This leads to a total market size of $7.266 billion. Other estimates show that the market size is around $10 billion.
AKI is defined as a sudden decrease in kidney function. It is generally measured by using serum creatinine levels (used to estimate Glomerular Filtration Rate), as well as Urinary Output. These methods are slow and nonspecific.
We propose to develop a biochip to diagnose AKI earlier using other urinary biomarkers.